Abeona Therapeutics Inc.
ABEOHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeAbeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. The $334.5M market capitalization puts ABEO squarely in small-cap range for its industry. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa.
Market Cap
$334.5M
Beta
1.32
P/E (TTM)
—
P/E (Fwd)
-31.34
EPS (TTM)
$-1.21
EPS (Fwd)
$-0.19
ROE
-43.1%
ROA
-24.6%
Cash
$146.8M
Total Debt
$19.9M
Free CF
-$73.4M
52W Change
-8.1%
Annual Financials
Cash vs Debt
Where ABEO stands vs its 150-day and 200-day moving averages
As of the September 2, 2026 close, ABEO finished 6.41% above its 150-day moving average ($5.62) and 9.32% above its 200-day moving average ($5.47). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ABEO overbought or oversold?
At the September 2, 2026 close, ABEO's RSI(14) was 23.6, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $146.8M in cash and $19.9M in debt, ABEO maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$73.4M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -43.1% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $1.4M (2022) to $5.8M (2025), reflecting a 312% increase over the period.
With cash comfortably exceeding debt, ABEO has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Abeona Therapeutics Inc.'s trajectory.